Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan;33(1):82-7.
doi: 10.1007/s00134-006-0447-4. Epub 2006 Nov 14.

Remifentanil-based sedation to treat noninvasive ventilation failure: a preliminary study

Jean-Michel Constantin  1 , Eric Schneider, Sophie Cayot-Constantin, Renaud Guerin, Francois Bannier, Emmanuel Futier, Jean-Etienne Bazin
Affiliations

Remifentanil-based sedation to treat noninvasive ventilation failure: a preliminary study

Jean-Michel Constantin et al. Intensive Care Med. 2007 Jan.

Abstract

Objective: To assess the feasibility and safety of remifentanil-based sedation during noninvasive ventilation (NIV) in patients with NIV failure.

Design and setting: Prospective clinical investigation in a 16-bed intensive care unit of a university hospital in France.

Patients: Thirteen patients in NIV failure due to discomfort and/or refusal to continue this ventilatory support: 10 with acute respiratory failure and 3 with acute hypercapnic respiratory failure.

Intervention: Patients were administered methylene blue and were sedated (Ramsay scale 2-3) by a continuous perfusion of remifentanil during NIV. Cardiorespiratory and ventilatory parameters, blood gas analysis, and adverse events were prospectively recorded.

Measurements and results: The 13 patients received a total of 125 NIV sessions, totaling 1200 h, of NIV under remifentanil-based sedation (mean remifentanil dose 0.1+/-0.03 microg/kg per minute). Three patients also required propofol. PaO2/FIO2 ratio increased from 134+/-69 to 187+/-43 mmHg after 1 h. In patients with acute respiratory failure respiratory rate decreased from 34+/-12 per minute before remifentanil to 25+/-4 per minute after 1h. In the three patients with acute hypercapnic respiratory failure PaCO2 decreased from 69+/-7 to 42+/-5 mmHg. Four patients required endotracheal intubation without aspiration pneumonia. Twelve of the 13 patients left the ICU.

Conclusion: This pilot study shows that remifentanil-based sedation is safe and effective in the treatment of NIV failure due to low tolerance.

PubMed Disclaimer

References

    1. Chest. 1998 Mar;113(3):768-73 - PubMed
    1. Anesthesiology. 1997 Sep;87(3):533-41 - PubMed
    1. Anesth Analg. 2003 Jan;96(1):33-8, table of contents - PubMed
    1. Crit Care. 2004 Feb;8(1):13-4 - PubMed
    1. ACP J Club. 2002 Sep-Oct;137(2):50 - PubMed